Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-02
2007-01-02
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S469000, C514S640000, C549S051000, C549S058000, C549S471000, C564S254000, C564S257000, C564S265000
Reexamination Certificate
active
10845687
ABSTRACT:
This invention provides estrogen receptor modulators having the structurewhere R1–R5are as defined in the specification; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4418068 (1983-11-01), Jones
patent: 5998402 (1999-12-01), Miller et al.
patent: 6288126 (2001-09-01), Lesuisse et al.
Mendelsohn, M. E. et al., “The Protective Effects of Estrogen on the Cardiovascular System,” New England Journal of Medicine 340: 1801-1811 (1999).
Epperson, C. N. et al., “Gonadal Steroids in the Treatment of Mood Disorders,” Psychosomatic Medicine 61: 676-697 (1999).
Crandall, C. J., “Estrogen Replacement Therapy and Colon Cancer: A Clinical Review,” Journal of Womens Health & Gender Based Medicine 8: 1155-1166 (1999).
Monk, D. et al., “Use of Estrogens for the Prevention and Treatment of Alzhimer's Disease,” Dementia & Geriatric Cognitive Disorders 11: 1-10 (2000).
Hurn, P. D. et al., “Estrogen as a Neuroprotectant in Stroke,” Journal of Cerebral Blood Flow & Metabolism 20: 631-652 (2000).
Calvin, M., “Oestrogens and Wound Healing,” Maturitas 34: 195-210 (2000).
Finking, G. et al., “Die Wirkungen von Östrogen im kardiovaskulären System,” Zeitschrift fur Kardiologie 89: 442-453 (2000) (English abstract included).
Brincat, M. P., “Hormone replacement therapy and the skin,” Maturitas 35: 107-117 (2000).
Al-Azzawi, F., “The menopause and its treatment in perspective,” Postgraduate Medical Journal 77: 292-304 (2001).
Moggs, J. G. et al., “Estrogen receptors: orchestrators of pleiotropic cellular responses,” EMBO Reports 2: 775-781 (2001).
Hall, J. M. et al., “The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling,” Journal of Biological Chemistry 276: 36869-36872 (2001).
McDonnell, D. P., Principles Of Molecular Regulation, Ch. 20, Humana Press, pp. 351-361 (2000) Totowa, New Jersey.
McKenna, N. J. et al., “Nuclear Receptor Coregulators: Cellular and Molecular Biology,” Endocrine Reviews 20: 321-344 (1999).
Quaedackers, M. E. et al., “4-Hydroxytamoxifen Trans-Represses Nuclear Factor-κB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)α, and Not through ERβ,” Endocrinology 142: 1156-1166 (2001).
Bhat, R. A. et al., “A Novel Human Estrogen Receptor β: Identification and Functional Analysis of Additional N-terminal Amino Acids,” Journal of Steroid Biochemistry & Molecular Biology 67: 233-240 (1998).
Pelzer, T. et al., “Estrogen Effects in the Myocardium: Inhibition of NF- κB DNA Binding by Estrogen Receptor-α and -β,” Biochemical & Biophysical Research Communications 286: 1153-7 (2001).
Levin, E. R., “Genome and Hormones: Gender Differences in PhysiologyInvited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors,” Journal of Applied Physiology 91: 1860-1867 (2001).
Levin, E. R., “Cellular Functions of the Plasma Membrane Estorgen Receptor,” Trends in Endocrinology & Metabolism 10: 374-377 (1999).
Green, S. et al., “Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A,” Nature 320: 134-9 (1986).
Kuiper, G. et al., “Cloning of a novel estrogen receptor expressed in rat prostate and ovary,” Proceedings of the National Academy of Sciences of the United States of America 93: 5925-5930 (1996).
Couse, J. F. et al., “Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse,” Endocrinology 138: 4613-4621 (1997).
Kuiper, G. et al., “Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β,” Endocrinology 138: 863-870 (1997).
Sar, M. et al., “Differential Expression of Estrogen Receptor- β and Esrogen Receptor-α in the Rat Ovary,” Endocrinology 140: 963-971 (1999).
Fitzpatrick, S. L. et al., “Expression of Estrogen Receptor- β Protein in Rodent Ovary,” Endocrinology 140: 2581-2591 (1999).
Cowley, S. M. et al., “Estrogen Receptors α and β Form Heterodimers on DNA,” Journal of Biological Chemistry 272: 19858-19862 (1997).
McDonnell, D. P., “Selective Estrogen Receptor Modulators (SERMs): A First Step in the Development of Perfect Hormone Replacement Therapy Regimen,” Journal of the Society for Gynecologic Investigation 7: S10-S15 (2000).
Goldstein, S. R. et al., “A Pharmacological review of selective oestrogen receptor modulators,” Human Reproduction Update 6: 212-224 (2000).
Pike, A. C. W. et al., “Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist,” Embo 18: 4608-4618 (1999).
Shiau, A. K. et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen,” Cell 95: 927-937 (Dec. 23, 1998).
Paige, et al., “Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β,” Proceedings of the National Academy of Sciences of the United States of America 96: 3999-4004 (1999).
Meyers, Marvin J, et al., “Estrogen Receptor Subtype-Selective Ligands: Asymmetric Synthesis and Biological Evaluation of cis- and trans-5,11-Dialkyl-5,6,11,12-tetrahydrochrysenes,”J. Med. Chem.(1999), 42(13), 2456-2468.
Black, L. J. et al., “Uterine Bioassay of Tamoxifen, Trioxifene and a New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26, 1453 (1980).
Yagi K., “Short Communications—A Simple Fluorometric Assay for Lipoperoxide in Blood Plasma,” Biochem Med 15:212-216 (1976).
Peele, D. B. et al., “Effects of Selection Delays on Radial Maze Performance: Acquisition and Effects of Scopolamine,” Pharmacology, Biochemistry, and Behavior, 29:143-150, (1988).
Monyer, H. et al., “Glucose deprivation neuronal injury in cortical culture,” 1989, Brain Research 483:347-354.
Wroblewski, F. et al. “Lactic Dehydrogenase Activity in Blood,” 1955, Proc. Soc. Exp. Biol. Med. 90:210-213.
Minutolo, F. et al., “Synthesis, Binding Affinity, and Transcriptional Activity of Hydroxy-and Methoxy-Substituted 3,4-Diarylsalicylaldoximes on Estogen Receptors alpha and beta,” Bioorganic and Medicinal Chemistry, 2003, 11:1247-1257.
Cohn Stephen Todd
Mewshaw Richard Eric
Dentz Bernard
Woodcock & Washburn LLP
Wyeth
LandOfFree
Aryl-carbaldehyde oxime derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-carbaldehyde oxime derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-carbaldehyde oxime derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3815837